De onderzoekers concluderen dat innovatieve behandelingen voor hematologische maligniteiten ‘may provide reasonable value for money.’
1.Saret CJ, Winn A, Shah G et al. Value of innovation in hemtologic malignancies: a systematic review of published cost-effectiveness analyses. Blood 2015; epub ahead of print